By Sheri Kasprzak
New York, March 16 - Elite Pharmaceuticals, Inc. said it has closed a $10 million private placement of series B convertible preferred stock.
The company sold 10,000 shares of the preferreds to a group of institutional and other investors.
The preferreds are initially convertible into 4,444,444 common shares at $2.25 each.
The conversion price is equal to the company's closing stock price on March 15.
The investors will receive 2,222,222 warrants. Half the warrants are exercisable at $2.75 each for five years and half are exercisable at $3.25 each for five years.
Indigo Securities, LLC was the placement agent.
Proceeds will be used to develop the company's portfolio of pain products.
Elite, based in Northvale, N.J., is a pharmaceutical company focused on developing oral controlled-release products.
| Issuer: | Elite Pharmaceuticals, Inc.
|
| Issue: | Series B convertible preferred stock
|
| Amount: | $10 million
|
| Shares: | 10,000
|
| Price: | $1,000
|
| Conversion price: | $2.25
|
| Conversion ratio: | Into 4,444,444 common shares
|
| Warrants: | 2,222,222
|
| Warrant expiration: | Five years
|
| Warrant strike price: | $2.75 for half, $3.25 for half
|
| Placement agent: | Indigo Securities, LLC
|
| Settlement date: | March 16
|
| Stock symbol: | Amex: ELI
|
| Stock price: | $2.25 at close March 15
|
|
|
© 2015 Prospect News.
All content on this website is protected by copyright law in the U.S. and elsewhere.
For the use of the person downloading only.
Redistribution and copying are prohibited by law without written permission in advance from Prospect News.
Redistribution or copying includes e-mailing, printing multiple copies or any other form of reproduction.
